Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CSL files biologics license application for human fibrinogen concentrate
Fibrinogen, also called Factor I, is a protein needed to form a blood clot. Fibrinogen levels in plasma determine the potential clotting ability and activity in the body.
Fibrinogen, also called Factor I, is a protein needed to form a blood clot. Fibrinogen levels in plasma determine the potential clotting ability and activity in the body.
Used in conjunction with the reading of standard digital chest X-rays, OnGuard is said to identify solitary pulmonary nodules that may be early-stage lung cancer. The contract streamlines
The transaction resulted in gross proceeds to Cardium of approximately $3.34 million, before placement agent fees and offering expenses and excluding any future proceeds from the exercise of
According to the terms of this agreement, Galapagos will receive more than $9 million over the course of the two year extension. BioFocus DPI runs a compound management
The decision ensures that the patent for Aciphex (rabeprazole sodium 20mg tablets) remains in force and also directs the FDA to change the effective date of Teva Pharmaceutical’s
The GeoVax vaccine is a DNA/MVA vaccine that uses recombinant DNA to prime the immune response and then a recombinant MVA virus to boost the immune response. MVA
CyGene’s StrokeScan analyzes genes that have been associated with the increased risk of stroke and the ‘alpha-galactosidase A’ gene that is responsible for Fabry disease. The StrokeScan is
These trials are designed to assess the blood pressure profile of naproxcinod, in comparison to ibuprofen and naproxen, using the Ambulatory Blood Pressure Monitoring (ABPM) technique. Results of
Study FLT-3501 assessed 182 patients, suffering from mild to moderate-severe persistent and reversible asthma, who were treated in accordance with the protocol. This randomized, open label, parallel group
Isotechnika will now open up the licensing process to companies with a strategic focus in this therapeutic area. The licensing process will be completed based on an accelerated